Cubicin: Spearheading Chiron's Biopharma Push in Europe
Executive Summary
Antibiotic Cubicin, which Chiron expects to file for European approval before year end, is key to the US group's biopharma push in Europe. New EMEA guidelines on anti-infectives may ease the drug's passage onto the European market. But it will still face stiff competition from other new anti-bacterials, most without the legacy of toxicity concerns that have dogged Cubicin.